Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans.

@article{Coleman2003EffectOA,
  title={Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans.},
  author={Nicholas S. Coleman and Luca Marciani and Elaine P. Blackshaw and Jeff Wright and Michael C. Parker and Tomoko Elizabeth Yano and Shiho Yamazaki and Piu Chan and Kathryn Wilde and Penny A. Gowland and Alan C. Perkins and Robin C Spiller},
  journal={Alimentary pharmacology & therapeutics},
  year={2003},
  volume={18 10},
  pages={
          1039-48
        }
}
BACKGROUND Although 5-HT3 antagonists have been used to treat chemotherapy-induced emesis and diarrhoea-predominant irritable bowel syndrome, the effects of 5-HT3 agonists in humans are unknown. AIM To determine the effect of MKC-733, a selective 5-HT3 receptor agonist, on upper gastrointestinal motility. METHODS Oral MKC-733 (0.2, 1 and 4 mg) was compared with placebo in three randomized, double-blind, cross-over studies in healthy males. Antroduodenal manometry was recorded for 8 h during… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Similar Papers

Loading similar papers…